COVID-19 Update / Guidelines for the treatment of children released, Remdesivir will not be used

There are fears that the third wave of Corona will prove to be dangerous in children. In view of this, governments have started taking steps. In this sequence, the Central Government has issued guidelines related to the treatment of children. The Ministry of Health has advised not to use Remdesivir injection in children.

Vikrant Shekhawat : Jun 10, 2021, 06:43 AM
New Delhi. There are fears that the third wave of Corona will prove to be dangerous in children. In view of this, governments have started taking steps. In this sequence, the Central Government has issued guidelines related to the treatment of children. The Ministry of Health has advised not to use Remdesivir injection in children.

The guidelines state that it is very important to pay attention to the use of steroids during treatment. It is very important to use it at the right time and in the right quantity. Also steroids should not be used without medical advice at all.

Use city scan wisely

Apart from this, it has also been advised to use City Scan in a proper way. It has been said in the guidelines that doctors should be very sensitive while conducting CT scan of children. On the other hand, remdesivir injection has been said that it should not be used in children due to lack of efficacy data.

Experts have expressed apprehension

Let us tell you, experts have expressed apprehension that the third wave of corona can prove to be dangerous for children. According to experts, the first wave of corona in the country had become a threat to the elderly, while the second wave proved to be dangerous for the young population. According to experts, the third wave of corona can prove to be fatal for children.

Vaccine trial has been given permission

For this reason, efforts are also being made to vaccinate children. Bharat Biotech, the manufacturer of India's indigenous vaccine Covaccine, has been given permission for trials in children. This trial will be done by Bharat Biotech on 525 volunteers. In this trial, 2 to 18 year olds will be included.